SCHEDULE: 683 Capital Discloses 7.86% Stake in IN8BIO

683 Capital Management, LLC and its affiliates have reported a 7.86% beneficial ownership stake in IN8BIO, Inc., including warrants.

Summary

• 683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman collectively beneficially own 770,445 shares of IN8BIO, Inc. Common Stock.
• This ownership represents approximately 7.86% of the company's outstanding Common Stock.
• The reported beneficial ownership includes warrants to purchase 45,808 Common Shares.
• The percentage calculation is based on 9,807,233 total shares, which includes 4,634,396 shares outstanding as of November 3, 2025, 5,127,029 shares issued in a private placement on December 19, 2025, and the 45,808 shares from currently exercisable warrants held by the reporting persons.
• The acquisition of these securities was not for the purpose of changing or influencing control of IN8BIO, Inc., nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by an institutional investor like 683 Capital Management, LLC, including warrants, is generally viewed positively as it signals confidence and a long-term investment perspective in IN8BIO, Inc.

Positives

• A significant institutional investor, 683 Capital Management, LLC, has taken a substantial stake (7.86%) in IN8BIO, Inc., potentially signaling confidence in the company's future prospects.
• The inclusion of warrants in the beneficial ownership suggests a long-term investment perspective and potential for increased equity stake.

Future Outlook

This filing does not contain any forward-looking statements or guidance from IN8BIO, Inc. or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

This filing indicates a significant investment by 683 Capital Management, LLC in IN8BIO, Inc. While the filing itself does not provide industry-specific analysis, such an investment by a capital management firm often reflects a belief in the long-term growth potential within the company's sector, which for IN8BIO (a known biotech company) would be the biotechnology and pharmaceutical industry.

Stakeholder Impact

• Shareholders: The entry of a significant institutional investor could be seen as a positive signal, potentially increasing investor confidence and liquidity.
• Company Management: A large shareholder may exert influence on strategic decisions, though the filing states the acquisition was not for changing or influencing control.

Key Dates

Recommendation

The filing indicates a significant beneficial ownership by 683 Capital Management, LLC, a reputable investment firm. While this signals institutional confidence in IN8BIO, Inc., a Schedule 13G primarily reports ownership and does not provide detailed financial performance or operational updates. Therefore, a 'hold' recommendation is prudent, suggesting existing investors maintain their position while monitoring future company developments and financial disclosures. New investors should conduct further due diligence beyond this ownership report.

Keywords

IN8BIO, 683 Capital Management, Ari Zweiman, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investment, Biotechnology, Healthcare